Blood thinner plus antiplatelet after iliac vein stent
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial looks at whether taking a blood thinner and an additional clot-prevention medicine (antiplatelet) after iliac vein stenting can improve treatment of certain deep vein clots. It may help prevent the clot from coming back or spreading, but it also increases bleeding risk, so careful eligibility screening is important.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a recent deep vein clot (DVT) in a leg along with blockage/narrowing of the iliac vein on the same side (>50%).
- The clot must be recent (not long-standing); your DVT start was within about 3 weeks.
- You plan to have treatment to remove the clot (percutaneous mechanical thrombectomy), with or without clot-dissolving treatment through a catheter.
- You will receive an iliac vein stent during that procedure or within 30 days after.
- You can take both a blood thinner and antiplatelet medicines safely (no known allergy/contraindication).
- Your kidney function is not too low (glomerular filtration rate is at least 60 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a procedure to remove an acute deep vein blood clot in the leg. It may help restore blood flow faster than standard treatment for certain clot locations.
This trial tests a procedure to remove blood clots from deep veins in the leg and pelvis. It aims to improve blood flow and reduce long-term leg damage. If you have a recent clot in these veins, you may be eligible.
This trial tests whether placing a stent (a small mesh tube) in the iliac vein can help heal chronic leg ulcers caused by prior blood clots. The goal is to improve blood flow and reduce symptoms.
This Phase 3 trial compares the best “blood thinner” approach for people who have a new clot in the leg (DVT) or lung (PE) and who already take antiplatelet medicines for heart or blood-vessel prevention. It aims to find an antithrombotic plan that lowers clot risk while managing bleeding risk.
This trial tests whether a blood thinner called rivaroxaban helps improve slow blood flow in heart arteries after a stent placement for a heart attack. It may help reduce complications by keeping the arteries open better.
This trial tests whether combining a clot-busting procedure (pharmaco-mechanical thrombolysis) with standard blood thinners works better than blood thinners alone for people with severe, recently formed deep vein clots in the upper leg.
Hear when a new Deep Vein Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.